(19)
(11) EP 2 602 258 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.09.2016 Bulletin 2016/39

(45) Mention of the grant of the patent:
19.03.2014 Bulletin 2014/12

(21) Application number: 13157396.6

(22) Date of filing: 26.09.2012
(51) International Patent Classification (IPC): 
C07D 417/12(2006.01)

(54)

N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamidmesylat-Monohydrat

Monohydrate de mesylate acétamide N-[5-(Aminosulfonyl)-4-méthyl-1,3-thiazol-2-yl]-N-méthyl-2-[4-(2-pyridinyl)phényl]

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 26.09.2011 EP 11007823

(43) Date of publication of application:
12.06.2013 Bulletin 2013/24

(62) Application number of the earlier application in accordance with Art. 76 EPC:
12762300.7 / 2598501

(73) Proprietor: AiCuris GmbH & Co. KG
42117 Wuppertal (DE)

(72) Inventors:
  • Dr. Schwab, Wilfried
    14542 Werder (DE)
  • Birkmann, Alexander
    42327 Wuppertal (DE)
  • Vögtli, Kurt
    5273 Oberhofen AG (CH)
  • Haag, Dieter
    4433 Ramlinsburg BL (CH)
  • Lender, Andreas
    42327 Wuppertal (DE)
  • Grunenberg, Alfons
    41539 Dormagen (DE)
  • Keil, Birgit
    40231 Düsseldorf (DE)
  • Rehse, Joachim
    42799 Leichlingen (DE)

(74) Representative: Arth, Hans-Lothar 
ABK Patent Attorneys Jasminweg 9
14052 Berlin
14052 Berlin (DE)


(56) References cited: : 
WO-A1-01/47904
 WO-A1-2006/103011
   
  • U. A. K. BETZ ET AL: "Potent In Vivo Antiviral Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 6, 1 June 2002 (2002-06-01), pages 1766-1772, XP055012766, ISSN: 0066-4804, DOI: 10.1128/AAC.46.6.1766-1772.2002
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).